MPM Injection 0.5 grams (Meropenem Trihydrate)

Adult dosage

As meropenem, administer 0.5 to 1 g (potency) per day divided into 2 to 3 doses administered by gradual intravenous infusion over at least 30 minutes. For suspected infections in pathogenic pneumonia, peritonitis, or neutropenic patients, administer 1 g (potency) by gradual intravenous infusion every 8 hours. For cystic fibrosis or meningitis, administer 2 g (potency) intravenously every 8 hours.

Children's dosage

For bacterial meningitis in children over 3 months of age, intravenous infusion at a rate of 40 mg per kg body weight every 8 hours for at least 30 minutes, depending on the pathogen’s susceptibility and the patient’s condition.

This medication should not be used in patients who have previously experienced shock symptoms due to it. Additionally, patients taking sodium valproate should not use this medication as it may lower the blood concentration of valproate and trigger seizures. Patients with allergic reactions to this medication or its components, or those who have experienced severe allergic reactions to other carbapenem or beta-lactam antibiotics (such as penicillin or cephalosporins) should not be administered this drug. Caution is necessary for patients with allergic tendencies or those who easily exhibit symptoms such as asthma and rashes. Patients with compromised renal function may have prolonged drug retention leading to central nervous system issues, necessitating dose reduction or increased dosing intervals. Patients with epilepsy or central nervous system disorders may experience seizures or consciousness disturbances when using this medication; careful observation is required. Patients with severely impaired liver function, the elderly, those who cannot take oral medications or are malnourished, and infants under 3 months should also be administered this drug with caution. During the use of this medication, serious allergic reactions such as shock or anaphylaxis may rarely occur, so thorough case history and skin reaction tests are recommended before administration, and close observation after administration is necessary. If hypersensitivity reactions such as skin rash, hives, itching, or fever occur, administration should be stopped immediately, and appropriate treatment should be sought. Periodic blood tests are necessary as leukopenia, anemia, and platelet abnormalities may occur, and treatment should be stopped in the presence of any abnormalities. Liver function abnormalities, acute hepatitis, jaundice, etc., may develop, so regular liver function tests are needed. Renal function may worsen; therefore, renal function assessments are also required, and abdominal pain and severe diarrhea may indicate serious intestinal diseases such as pseudomembranous colitis, necessitating immediate cessation of the drug. If central nervous system symptoms such as seizures or consciousness disturbances occur, the medication should be discontinued, and patients with renal or central nervous system disorders should be especially cautious. Respiratory issues, asthma symptoms, pneumonia, and pulmonary edema may rarely occur, so if respiratory symptoms develop, healthcare providers should be informed immediately. Severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis may occur, so the skin condition should be closely monitored. Disruption of normal flora such as stomatitis or candidiasis may occur, thus maintaining proper oral hygiene is important. Bleeding tendencies due to vitamin K deficiency may become evident, so immediate reporting of any bleeding symptoms is essential, and symptoms of vitamin B deficiencies should also be noted. Cardiac side effects such as heart failure, cardiac arrest, and arrhythmias have been reported, so patients with cardiac diseases should be careful. Neuropsychiatric symptoms such as insomnia, confusion, and hallucinations may occur; patients should notify healthcare providers of any unusual symptoms. Injection site inflammation, pain, and swelling may occur, so the injection site should be monitored. This medication should only be used for the minimum duration necessary to prevent the emergence of resistant bacteria, and if susceptibility is not confirmed, it is advisable to switch to another medication. Pregnant women or those who could become pregnant should use this medication only when the benefits outweigh the risks, as its safety has not been established. Breastfeeding mothers should avoid using this medication, as it can be secreted in breast milk. Use in infants under 3 months is not advisable as safety and efficacy have not been established. Elderly individuals may exhibit increased susceptibility to side effects due to decreased bodily functions, thus dosing and intervals should be adjusted carefully.

Serious side effects

Shock, anaphylaxis, severe allergic reactions, severe skin reactions, toxic epidermal necrolysis (Lyell's syndrome), drug reaction (DRESS syndrome), erythema multiforme, acute generalized exanthematous pustulosis (AGEP), fulminant hepatitis, liver failure, jaundice, hepatic impairment, acute renal failure, severe renal impairment, pseudomembranous colitis, severe diarrhea, severe edema, respiratory distress, asthma, pleural effusion, interstitial pulmonary disease

Mild side effects

• Rash
• hives
• warmth
• erythema
• itching
• fever
• redness
• generalized flushing
• angioedema
• pancytopenia

This medication should be stored in a sealed container to prevent exposure to air or moisture. The optimal storage temperature is between 1 and 30 degrees Celsius at room temperature. Proper storage helps maintain the medication's effectiveness.

Appearance

Vial filled with crystalline powder ranging from white to pale yellow

Package unit

10 vials